Evidence map›Paper›PMID 25430556›Full record

SynthesisScientific reports2014

Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis.

Xiao Zhang, Wenhao Weng, Wen Xu, Yulan Wang, Wenjun Yu, Xun Tang, Lifang Ma, Qiuhui Pan, Jiayi Wang, Fenyong Sun

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiao ZhangDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Wenhao WengDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Wen XuDepartment of Clinical laboratory medicine, Zhongshan Hospital, Fudan University, Shanghai, China, 200032.
Yulan WangDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Wenjun YuDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Xun TangDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Lifang MaDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Qiuhui PanDepartment of Central Laboratory, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Jiayi WangDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.
Fenyong SunDepartment of Clinical laboratory medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China, 200072.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The association between B-cell lymphoma 2 (Bcl-2) polymorphism and cancer is under debate and remains elusive. This meta-analysis was performed to evaluate the relationships of Bcl-2 -938 C>A polymorphism (rs2279115) with susceptibility and prognosis of cancer. Odds ratios (ORs) were used to measure the association between Bcl-2 polymorphisms and cancer risk. Hazard ratios (HRs) were used to measure the association between Bcl-2 polymorphisms and cancer prognosis. On the basis of 26 studies about Bcl-2 -938C>A polymorphism and cancer, we found Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in dominant model (OR = 1.12, 95%CI: 1.00-1.25, P = 0.04), recessive model (OR = 1.38, 95%CI: 1.11-1.71, P = 0.004), allelic model (OR = 1.15, 95%CI: 1.04-1.28, P = 0.007) and homozygote comparison(OR = 1.44, 95%CI: 1.11-1.87, P = 0.006). Furthermore, Bcl-2 -938 C>A polymorphism was significantly associated with increased cancer risk in Asians but not in Caucasians. Moreover, Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77-1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65-1.30, P = 0.63; AC vs CC: OR = 0.94, 95%CI: 0.80-1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69-2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48-2.04, P = 0.97). Studies with larger samples and gene-environment interactions are needed to validate our findings.

Indexed as

AgedAllelesAsian PeopleCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedNeoplasmsPolymorphism, GeneticPrognosisProto-Oncogene Proteins c-bcl-2RiskRisk FactorsWhite PeopleBCL2 protein, humanProto-Oncogene Proteins c-bcl-2

Identifiers

PMID25430556
PMCPMC5384243

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.